

Petitioner's Updated Exhibit List of 6/4/2020

Ex #	Exhibit
1001	U.S. Patent No. 8,791,154 B2 (“154 Patent”)
1002	U.S. Patent No. 9,533,053 B2 (“053 Patent”)
1003	WO 2008/015695 A2 (“Bhowmick”)
1004	YANNI et al., “The <i>In Vitro</i> and <i>In Vivo</i> Ocular Pharmacology of Olopatadine (AL-4943A), an Effective Anti-Allergic/Antihistaminic Agent,” <i>Journal of Ocular Pharmacology and Therapeutics</i> , Volume 12, Number 4, 1996, pp. 389-400 (“Yanni”)
1005	U.S. Pat. No. 6,995,186 B2 (“Castillo”)
1006	U.S. Pat. Pub. No. 2011/0082145 A1 (“Schneider”)
1007	U.S. Pat. No. 5,641,805 (“Hayakawa”)
1008	File Wrapper for U.S. Patent No. 8,791,154 B2
1009	File Wrapper for U.S. Provisional Appl. No. 61/487,789
1010	File Wrapper for U.S. Provisional Appl. No. 61/548,957
1011	Physician’s Desk Reference - PATANOL®; PATADAY® (“PDR”)
1012	Handbook of Pharmaceutical Excipients
1013	David B. Troy, <i>Remington: The Science and Practice of Pharmacy</i> , Philadelphia College of Pharmacy and Science, 21st ed., 229, 856-866 (2005)
1014	Declaration of Dr. Laskar
1015	<i>Argentum Pharm. LLC v. Alcon Research, Ltd.</i> , IPR2016-00544, Paper 8 (P.T.A.B. July 18, 2016)
1016	<i>Apotex, Inc. v. Alcon Research Ltd.</i> , IPR2016-01640, Paper 2 (P.T.A.B. Aug. 18, 2016)
1017	<i>Alcon Research, Ltd. v. Watson Labs.</i> , 1-15-cv-01159 (D. Del.) Paper 69 (November 18, 2016)

1018	Abelson & Gomes, “Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing,” <i>Expert Opinion on Drug Metabolism & Toxicology</i> , 4:4, 453-461 (2008) (“Abelson”)
1019	Pharmaceutical Calculations, 13th ed., Ansell, 2010
1020	U.S. Patent No. 6,770,675
1021	<i>Argentum Pharm. LLC v. Alcon Research, Ltd.</i> , IPR2016-00544, Paper 1 (P.T.A.B. Feb. 2, 2016)
1022	<i>Apotex, Inc. v. Alcon Research Ltd.</i> , IPR2016-01640, Paper 3 (P.T.A.B. Aug. 18, 2016)
1023	<i>Apotex, Inc. v. Alcon Research Ltd.</i> , IPR2016-01640, Paper 8 (P.T.A.B. Oct. 5, 2016)
1024	<i>Apotex, Inc. v. Alcon Research Ltd.</i> , IPR2016-01640, Paper 9 (P.T.A.B. Nov. 30, 2016)
1025	Abelson & Loeffler, <i>Conjunctival Allergen Challenge: Models in the Investigation of Ocular Allergy</i> , <i>Current Allergy and Asthma Reports</i> 3:363-368 (2003)
1026	Eiichi Uchio, <i>Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops</i> , <i>Clinical Ophthalmology</i> 2(3):525-531, 527-528 (2008)
1027	Abelson et al., “ <i>Efficacy of Once-Daily Olopatadine 0.2% Ophthalmic Solution Compared to Twice-Daily Olopatadine 0.1% Ophthalmic Solution for the Treatment of Ocular Itching Induced by Conjunctival Allergen Challenge</i> ,” <i>Current Eye Research</i> 32:1017-1022 (2007)

1028	Leonardi, et al., “ <i>The anti-allergic effects of a cromolyn sodium-chlorpheniramine combination compared to ketotifen in the conjunctival allergen challenge model,</i> ” <i>European J. of Ophthalmology</i> 13(2):128-133 (2003)
1029	U.S. Patent Publication No. 2008/0085922
1030	<i>Alcon Research, Ltd. v. Watson Labs.</i> , 1-15-cv-01159 (D. Del.) Paper 155 (March 1, 2018)
1031	https://www.pazeodrops.com/
1032	Orange Book entry for PAZEO®
1033	EP 0214779
1034	U.S. Pat. No. 4,871,865
1035	EP 0235796
1036	U.S. Pat. No. 5,116,863
1037	CV of Dr. Paul Laskar
1038	Handbook of Chemistry and Physics 2006, 87th ed.
1039	U.S. Publication No. 2004/0198828 (“Abelson”)
1040	Nandi et al., “NANDI et al., “Synergistic Effect of PEG-400 and Cyclodextrin to Enhance Solubility of Progesterone,” <i>AAPS PharmSciTech</i> 2003; 4 (1), pp 1-5.”

1041	LOFTSSON et al., "Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye," Acta Ophthalmologica Scandinavica, 2002, pp. 144-150.
1042	Declaration of Dr. S. Craig Dyar
1043	CV of Dr. S. Craig Dyar
1044	Transcript of Telephone Conference Call 5/28/2020